These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 2390644

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 23. Prevention and treatment of relapse by bone marrow transplantation.
    Slavin S, Weiss L, Ackerstein A, Vourka-Karussis U, Morecki S, Or R, Nagler A, Kapelushnik J, Delukina M, Drakos P.
    Bone Marrow Transplant; 1993; 12 Suppl 3():S54-6. PubMed ID: 8124259
    [Abstract] [Full Text] [Related]

  • 24. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S, Kamisaku H, Sado T.
    Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
    [Abstract] [Full Text] [Related]

  • 25. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
    Weiss L, Reich S, Slavin S.
    Bone Marrow Transplant; 1995 Sep; 16(3):457-61. PubMed ID: 8535320
    [Abstract] [Full Text] [Related]

  • 26. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I, Weiss L, Abdul-Hai A, Kasir J, Reich S, Slavin S.
    Cancer Res; 2005 Nov 01; 65(21):9735-40. PubMed ID: 16266994
    [Abstract] [Full Text] [Related]

  • 27. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 28. Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells.
    Mukaide H, Adachi Y, Koike-Kiriyama N, Suzuki Y, Minamino K, Iwasaki M, Tsuda M, Nakano K, Koike Y, Shigematsu A, Kamiyama Y, Ikehara S.
    Int J Oncol; 2007 Jun 01; 30(6):1309-15. PubMed ID: 17487350
    [Abstract] [Full Text] [Related]

  • 29. In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation.
    Kedar E, Tsuberi BZ, Landesberg A, Anafi M, Leshem B, Gillis S, Urdal DL, Slavin S.
    Bone Marrow Transplant; 1988 Jul 01; 3(4):297-314. PubMed ID: 3048495
    [Abstract] [Full Text] [Related]

  • 30. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ, Thompson JS, Jennings CD, Brown SA.
    Transplantation; 1995 Oct 27; 60(8):821-7. PubMed ID: 7482742
    [Abstract] [Full Text] [Related]

  • 31. Effects of ex vivo activated immune cells on syngeneic and semi-allogeneic bone marrow transplantation in mice.
    Yang G, Tan J, Wei G, Deng Y, Chen H, Yang D.
    Transpl Immunol; 2006 Nov 27; 16(3-4):166-71. PubMed ID: 17138049
    [Abstract] [Full Text] [Related]

  • 32. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
    Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE.
    Biol Blood Marrow Transplant; 1996 Oct 27; 2(3):118-25. PubMed ID: 9199754
    [Abstract] [Full Text] [Related]

  • 33. Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1).
    Abdul-Hai A, Weiss L, Ben-Yehuda A, Ergas D, Shapira MY, Slavin S.
    Bone Marrow Transplant; 2007 Nov 27; 40(9):881-9. PubMed ID: 17704792
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).
    Kedar E, Or R, Naparstek E, Zeira E, Slavin S.
    Bone Marrow Transplant; 1988 Mar 27; 3(2):129-40. PubMed ID: 3048477
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.
    Leshem B, Tsuberi BZ, Lebendiker Z, Anafi-Ayalon M, Shalit M, Weiss L, Slavin S, Kedar E.
    Transplantation; 1987 Jun 27; 43(6):814-7. PubMed ID: 2954282
    [Abstract] [Full Text] [Related]

  • 40. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K, O'Donnell RW, Cockett AT.
    J Biol Response Mod; 1988 Feb 27; 7(1):43-53. PubMed ID: 3259620
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.